BC001+Sintilimab+XELOX
Phase 1Biologic
BC001+Sintilimab+XELOX is one of 51 biologic programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
55 competitors in Gastroesophageal Junction Adenocarcinoma
#DrugCompanyPhaseTrials
1Eloxatin
TevaPhase 3
Lenvima
EisaiApproved
Elunate
TakedaApproved
Taxol
TevaPhase 3
Keytruda
Merck & Co.Phase 3
Beyfortus
BeiGenePhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Taxotere
AAvyxa
Phase 3
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BC001+Sintilimab+XELOX. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details